Janus Henderson Global Life Sciences Fund
Actively managed U.S. stock fund
As of its 2026 Q2 report, Janus Henderson Global Life Sciences Fund held 107 positions with $5.81B in net assets. Its ten largest holdings made up 42.4% of the fund. The JAGLX share class costs 0.92% a year. Over the 12 months to May 2026, JAGLX returned 31.8%, with dividends reinvested. In 2026 Q2 it added 39 new positions and exited 36.
Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.
The fund invests primarily in equity securities of U.S. and foreign companies in the life sciences sector—including pharmaceuticals, biotechnology, health care services, medical devices, agriculture, and cosmetics—selected through bottom-up analysis for growth potential, management quality, competitive advantages, and returns on capital. Portfolio management incorporates environmental, social, and governance factors alongside fundamental analysis and applies screens to avoid UN Global Compact violators and to hold at least 80% of assets in issuers with an MSCI ESG rating of BB or higher. Because security selection depends on portfolio management's assessment of individual companies, fund performance may diverge from that of life sciences equity benchmarks.
What you own
| Company | Weight | Value | Shares | Reported price |
|---|---|---|---|---|
9.41% | $546.44M | 455.6K | $1,199.43 | |
7.09% | $411.81M | 1.6M | $253.97 | |
ABBVAbbVie, Inc. | 4.67% | $271.02M | 1.1M | $251.64 |
4.54% | $263.63M | 634.3K | $415.63 | |
AstraZeneca plc | 3.93% | $228.27M | 1.2M | $187.11 |
3.02% | $175.40M | 936.6K | $187.28 | |
ARGXArgenx SE | 2.63% | $152.70M | 164.6K | $927.77 |
NVSNovartis AG | 2.56% | $148.84M | 949.7K | $156.72 |
2.33% | $135.41M | 270.1K | $501.36 | |
2.19% | $127.00M | 379.4K | $334.79 |
Reported price is the fund's own reported value divided by its own reported shares at 2026-06-30 — not a live quote, and not what the fund paid.
All 107 holdings, with the share counts as filed, open with a free account.
What the fund is made of
Percentages are of fund net assets. Rounding, liabilities and short positions can make totals differ from 100%.
| Stocks | 99.11% |
| Cash & short-term | 0.90% |
| Other | 0.01% |
Derivatives are shown at market value, not notional exposure.
By sector
- Health Care
- 82.6%
- International
- 15.7%
- Cash
- 0.9%
- Other
- 0.9%
How it has done
JAGLX share class · total returns with dividends reinvested
Volatility over the last 12 months: 14.73%. Past returns are a record, not a forecast.
Jun 2026 has been filed since the trailing figures were struck, so it is not in the table above or the curve — every figure here shares one cut-off, which is what makes them comparable with other funds.
The 7 share classes hold the same portfolio
| Share class | Expense ratio | 1 year | 3 years | 5 years | Worst fall |
|---|---|---|---|---|---|
| 0.92% | +31.84% | +40.11% | +42.81% | -17.73% | |
| 1.00% | +31.73% | +39.73% | +42.21% | -17.78% | |
| 1.79% | +30.77% | +36.67% | +37.10% | -18.23% | |
| 0.78% | +32.00% | +40.63% | +43.76% | -17.65% | |
| 1.19% | +31.47% | +38.97% | +40.84% | -17.91% | |
| 0.81% | +31.99% | +40.52% | +43.52% | -17.67% | |
| 0.68% | +32.12% | +41.04% | +44.45% | -17.60% |
These classes hold the same portfolio, so the 7.35pp spread over 5 years is the cost difference between them — roughly 1.47pp a year — not a difference in what they own.
Fees & fund details
Janus Henderson Global Life Sciences Fund is an actively managed U.S. equity fund.
- Asset class
- Equity
- Region
- United States
- Management
- Actively managed
- Fund type
- Open-end fund
- Expense ratio, by class
- 0.68% – 1.79%· JAGLX 0.92%
- Portfolio turnover
- 30.00% a year · as of 2026 Q1
Turnover is how much of the portfolio was replaced in a year.
Classified from what the fund holds, not from its name · 2026 Q2. The summary is a paraphrase of the prospectus; the objective is verbatim.
What changed this quarter
Positions that entered or left the fund since its previous filing. Positions that were only resized are not listed.
39 new· the largest 8
36 exited· the largest 8
Understand how this fund fits with the rest.
Explore shared holdings, compare funds and follow their businesses with your connected AI:
- “Where do my funds overlap — JAGLX, QQQ and the fund in my 401(k)?”
- “How do this fund’s ten biggest holdings stack up against each other?”
- “For my target-date fund, what’s the real stock-and-bond mix once you look through it?”